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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2014, TaiwanBackground: Elevated serum levels of neuron-specific enolase (NSE) was initially assumed to
be specific to neuronal tumors (particularly neuroblastoma), but is now known to accompany
nontumoral conditions and tumors other than neuroblastomas. There is a need to establish
normal ranges for NSE, especially in early infancy. The aims of this study were to determine
reference values for NSE in newborns and young infants and to assess whether NSE levels in
early infancy (i.e., preterm infants and term infants) differ from the adult reference range
for this enzyme.
Methods: We enrolled 140 healthy babies, which included 40 preterm newborns (3e15 days
old and born at 28e42 weeks gestation), 40 term newborns (< 1 month old and born at term),
and 60 young infants 1e3 months old (nZ 20 per subgroup of 1-, 2-, and 3-month-old infants).
The determination of NSE levels was performed by the electrochemiluminescence immuno-
assay (ECLIA) method using the Elecysys 2010 device (Roche Diagnostics, Mannheim, Ger-
many). The mean serum NSE levels for the preterm newborns was 21.83  15.06 ng/mL
[95% confidence interval (95%CI), 16.95e26.71 ng/mL]; term newborns, 18.06  12.83 ng/
mL (95%CI, 13.94e22.19 ng/mL); and young infants, 9.09  4.38 ng/mL (95%CI, 7.96
e10.23 ng/mL). The mean serum NSE level for infants 1e3 months old was within the ECLIA
kit’s normal range (4.7e18 ng/mL for adults), whereas the corresponding means for the pre-
term and term newborns were higher (p < 0.001, for both).University Faculty of Medicine, Department of Pediatrics, Division of Neonatology 06500,
ail.com (A. Abbasoglu).
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term and term age groups.
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reserved.1. Introduction
Tumor markers are substances that can be detected
immunohistochemically on the cell surface or are secreted
from tumor cells into blood, urine, and body fluids.1,2
Neuron-specific enolase (NSE) is a glycolytic enzyme that
catalyzes the conversion of 2-phosphoglycerate to phos-
phoenolpyruvate. This enzyme is a 78-kD gamma-
homodimer and is the dominant enolase-isoenzyme in
neuronal and neuroendocrine tissues. The biological half-
life of NSE in body fluids is approximately 24 hours.2,3
Initial predominant isoforms of the enzyme are aa di-
mers. Once cells begin to divide and migrate during
embryological development, the aa dimers are transformed
into gg dimers. Because increased levels of gg dimers occur
during neurogenesis and early neuronal differentiation, NSE
is a good indicator of neuronal maturation and differenti-
ation.4 It is a marker for all types of neurons and for all
neuroendocrine or paraneuronal cells. Initiation of NSE
production occurs late in neural differentiation, which
makes NSE a useful indicator of neural maturation.2,5
When neuronal damage occurs and/or the integrity of the
bloodebrain barrier becomes impaired, NSE is released into
cerebrospinal fluid (CSF) and eventually into circulating
blood. When NSE was first described, it was believed to be a
specific marker for neuronal tumors, especially for neuro-
blastoma. Neurogenic tumors may indeed result in elevated
blood levels of NSE; however, it has been shown that elevated
NSE levels can also be associatedwithmany other tumors and
various clinical conditions.6,7 Increased serum NSE may be
detected in patients with conditions such as hypoxia after
myocardial infarction, cell damage associated with the
central and peripheral nervous system, subarachnoid hem-
orrhage, traumatic brain damage, GuillaineBarre´ syndrome,
bacterial meningitis, encephalitis, sepsis, pneumonia, liver
disease, and neonatal hyperbiluribinemia.8e14
Greater use of ultrasonography during the prenatal and
newborn periods has increased the likelihood of detecting
asymptomatic masses and very common neoplasms
(including neuroblastoma) during these phases.15 Adrenal
masses smaller than 5 cm without metastases can be
identified ultrasonographically during the intrauterine
period and in premature babies, neonates, and in early
infancy (< 3 months of age). However, such masses can also
be detected through a combination of periodic ultrasound
and biochemical testing for parameters such as vanillyl-
mandelic acid (VMA), NSE, or ferritin.16 For this reason, it is
important to establish reference values for NSE in newborns
and very young infants. The aims of this study were to
determine reference values for NSE in newborns and young
infants, and to assess whether NSE levels in early infancy
(i.e., preterm infants and term infants) differ from the
adult reference range for this enzyme.2. Methods
The participants were 140 healthy preterm newborns or
term infants younger than 3 months old who were examined
between May 2010 and September 2010 in the Department
of Neonatology and the Department of Pediatrics at Bas-
kent University (Ankara, Turkey). The exclusion criteria
were a low Apgar score (< 6 at 1 minute or at 5 minutes), a
severe congenital abnormality, intraventricular hemor-
rhage, necrotizing enterocolitis, profound or suspected
infection, development of infection within 3 days after
serum sampling for the study, and pathological hyper-
bilirubinemia. The study was approved by the hospital’s
Ethical Research Committee. Written informed consent was
obtained from the parents of each participant.
Each child’s sex, gestational age, mode of delivery, birth
weight, weight for gestational age, Apgar scores at 1 minute
and 5 minutes, and serum bilirubin level were recorded. The
serum NSE levels were also determined (see details later).
The babies were enrolled consecutively to meet target
sample sizes for specific age groups that were categorized
as follows: 40 preterm newborns (3e15 days old and born at
28e42 weeks gestation); 40 term newborns (< 1 month old
and born at term), and 60 young infants 1e3 months of age
(n20 per subgroup of 1-, 2-, and 3-month-old infants). Each
preterm and term newborn underwent blood testing at
least 72 hours after birth. Each baby in the young infant
group had blood tested within the first 2 weeks of the
month of life they were in at the time of the study.
Serum samples were collected and stored at 20C until
analysis. All samples were tested together after the target
total sample size was reached. Testing for NSE was per-
formed using a commercial electrochemiluminescence
immunoassay (ECLIA) kit (Elecysys 2010 kit; Roche Di-
agnostics, Mannheim, Germany). Any infant with elevated
serum NSE level, based on this kit’s reference threshold
(i.e., NSE > 30 ng/mL) was clinically evaluated and un-
derwent repeat NSE testing, if necessary.
Descriptive statistics (i.e., mean values) and 95% confi-
dence intervals (95%CIs) were calculated for each group
and subgroup NSE findings. The ShapiroeWilk test was used
to assess whether variables were normally distributed. One-
way analysis of variance (ANOVA) and the Tukey honest
significant difference test were used to compare the mean
ages for the three main study groups. The Student t test
was used to compare the group means for other variables.
Relationships between variables were tested using Spear-
man’s rho correlation analysis.
3. Results
One baby with an elevated NSE level (96.21 ng/mL) had
sepsis and had to be removed from the study. In total, 139
116 A. Abbasoglu et alserum NSE values were evaluated (Table 1, Figure 1). The
mean serum NSE levels for the preterm newborns was
21.83  15.06 ng/mL (95%CI, 16.95e26.71 ng/mL); term
newborns, 18.06  12.83 ng/mL (95%CI,
13.94e22.19 ng/mL); and young infants, 9.09  4.38 ng/mL
(95%CI, 7.96e10.23 ng/mL). The mean serum NSE levels for
the 1-, 2-, and 3-month-old subgroups of young infants were
8.92  4.13 ng/mL, 7.63  3.91 ng/mL, and
10.73  4.70 ng/mL, respectively. The highest NSE level in
each of the three main groups was 59.36 ng/mL (for pre-
term infants), 59.80 ng/mL (for term infants), and
21.40 ng/mL (for young infants). The highest NSE levels in
each of the young infant subgroups were 16.80 ng/mL (for
1-month-old infants), 14.05 ng/mL (for 2-month-old in-
fants), and 21.40 ng/mL (for 3-month-old infants).
The mean NSE levels of the preterm and term groups
were significantly higher than the NSE levels in the young
infants group (p < 0.001 for both). There was no significant
association between the serum NSE level and the serum
total bilirubin level or between the serum NSE level and
birth weight (p Z 0.05 for both; Figures 2A and 2B). The
serum NSE level was negatively associated with Apgar
scores at 1 minute and at 5 minutes (correlation co-
efficients r Z 0.228 and r Z 0.246, respectively;
p Z 0.043 and p Z 0.029, respectively).4. Discussion
Our main finding in this study was that the mean serum NSE
level for infants 1e3 months old was within the ECLIA kit’s
normal range (i.e., 4.7e18 ng/mL for adults), whereas the
corresponding means for the preterm and term newborns
were higher. The 95%CI for the group of infants 1e3 months
old was within the kit’s reference range, whereas the 95%
CIs for the preterm and term groups both exceeded the
upper limit of this range.
Many factors may be associated with an elevation in the
serum NSE level.11,17e19 Hypoxia during the perinatal period
is the most important factor, followed by intracranial hem-
orrhage and infection.19e21 We investigated only healthy
infants in our study; however, prematurity is linkedwith high
morbidity and we therefore excluded preterm infants with
intracranial hemorrhage, infection, and perinatal hypoxia.
Knitzel et al22 investigated 192 healthy term newborns to
establish reference values for NSE in cord blood. They
excluded babies who had infections, hypoxia, and acidosis.Table 1 Serum neuron-specific enolase results for the study gr
Group/subgroup n
Mean  SD 95% confidence
interval
Preterm 39 21.83  15.06 16.95e26.71
Term 40 18.06  12.90 13.94e22.19
Young infants 60 9.09  4.38 7.96e10.23
1 month old 20 8.92  4.13 6.95e10.85
2 months old 20 7.63  3.91 5.80e9.46
3 months old 20 10.73  4.70 8.53e12.93
n Z number; NSE Z neuron-specific enolase; SD Z standard deviatioKnitzel et al22 observed that themedianNSEwas 8 ng/mL and
the range for the 5the95th percentile was 4.8e19.4 ng/ They
concluded that cord blood NSE levels above this range in
healthy term infants are associated with perinatal stress.
The median serum NSE level for our 40 healthy term new-
borns was 14.53 ng/mL. Knitzel et al22 evaluated cord blood
(which likely reflect perinatal hypoxia), whereas we studied
serum samples that were collected at least 72 hours after
birth with the intent of eliminating the effects of perinatal
hypoxia. We suspect that the effects of perinatal hypoxia
persisted in our sample after birth and that the 72-hour
period may have been insufficient to eliminate these ef-
fects. This is supported by our finding of a negative correla-
tion between the NSE level and the Apgar score. Our
observations suggest that increased NSE early after birth
could be because of subclinical hypoxia.
Ekmektzoglou et al23 studied adults with acute ischemic
stroke and observed that serum NSE levels reached their
maximum at 48 hours postevent. They postulated that the
bloodebrain barrier leakage caused high serum NSE levels
after the stroke. In neonates and very young infants, the
bloodebrain barrier is immature and neuronal development
is incomplete. Similar to the process postulated for stroke
patients, it is possible that the status of the bloodebrain
barrier in newborns and very young infants could explain
the broad range of serum NSE levels that we observed in our
groups of healthy babies with no history of hypoxia.
A study of 112 healthy newborns and their mothers
revealed that NSE levels in the neonates’ umbilical arteries
was in the range of 10e140 ng/mL and venous blood was in
the range of 8.8e92 ng/mL.24 On the 3rd day of life, venous
blood samples were obtained from 18 neonates and the NSE
levels ranged 11e200 ng/mL. The maternal NSE levels
(range, 3e14 ng/mL) were lower than all neonatal levels
that these authors observed in their study, which suggested
independent fetal production of these proteins. The au-
thors concluded that the high levels had not been caused by
pre- or perinatal trauma or hypoxia because only healthy
babies were investigated. A possible explanation for this is
that immaturity of the bloodebrain barrier permitted some
passage of these brain-specific proteins without underlying
damage. Another possible explanation is that the NSE
measured was not of brain origin, but originated from
different sources (e.g., thymus and fat tissue) during the
fetal period. In our study, we observed that the preterm
and term groups had significantly higher mean serum NSE
than the commercial kit’s reference range for adults.oups.
Serum NSE (ng/mL)
Minimum Maximum Median Interquartile
range
4.12 59.36 15.83 18.83
3.67 59.80 14.53 14.87
1.49 21.40 8.60 6.89
3.33 16.80 8.70 5.33
1.49 14.05 6.77 6.63
3.66 21.40 10.90 4.98
n.
Figure 1 Serum neuron-specific enolase (NSE) levels in the study groups.
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nounced in the preterm babies. This may be related to
factors such as heat exchange, inflation of the lungs, and
oxygenation during perinatal adaptation.
In small premature babies, intraventricular bleeding al-
ters NSE levels. Pellicer et al25 observed the NSE level in the
CSF of 39 preterm neonates (29.4  2.2 gestational weeks)
with known risk factors for brain damage. They docu-
mented brain damage by cerebral ultrasound and measured
the NSE level by enzyme immunoassay. They found a CSF
NSE level of 26.2  8.1 ng/mL in babies with normal cere-
bral ultrasound and 144.8  21.5 ng/mL in babies who had
developed periventricular hemorrhage with paranchymal
involvement during the 1st week of life. The increase in CSF
NSE value was statistically significant (p < 0.005). They
concluded that NSE is a marker for neuronal damage in the
prenatal period. Birth hypoxia and intracranial hemorrhage
are two potentially important factors for increased serum
NSE levels. Our study only included babies with 1- andFigure 2 Relationships between serum neuron-specific enolase (
birth weight (B).5-minute Apgar scores > 6. However, this scoring method is
subjective and birth hypoxia is more accurately assessed by
analyzing cord blood gases at birth. We did not analyze cord
blood gases and this was a limitation of our study. The
routine practice at our hospital is that all babies who are
born earlier than 32 weeks gestation undergo cranial ul-
trasonography. None had intracranial hemorrhage. We
found no correlation between a high serum NSE level and
intracranial hemorrhage.
High serum NSE levels have been detected in pediatric
patients with septic shock.26,27 Severe sepsis and septic
shock lead to deficiencies of oxygen and glucose, which are
necessary for brain development and normal neurological
function. When oxygen and glucose are deficient, reactive
oxygen radicals and cytokines are released and injure the
developing brain. The resulting damage to the bloodebrain
barrier leads to a rise in the serum NSE level. In our study,
we excluded babies with severe infection, but we did not
exclude very small premature infants who were receivingNSE) level and total bilirubin (A) and between serum NSE level
118 A. Abbasoglu et alprophylactic antibiotics. Our findings of higher serum NSE
levels in preterm and term newborns were not associated
with sepsis or septic shock.
Akman et al28 investigated correlations between an
increased serum NSE level and serum bilirubin, and be-
tween increased an serum NSE level and auditory neurop-
athy. They observed no relationship between serum NSE
and serum bilirubin level. The authors did find that infants
with serum bilirubin > 25 mg/dL had higher serum NSE
values than infants with serum bilirubin levels < 13 mg/dL.
Serum bilirubin must attain this level because of gestational
week and postnatal day to cross the bloodebrain barrier
and cause neuronal damage. Akman et al28 concluded that
the fact that this level was not exceeded explained why
they found no statistically significant correlation between
serum NSE and serum bilirubin. We also found no significant
relationship between the serum NSE levels and serum bili-
rubin level.
In Turkey, various methods and laboratory kits have been
used to measure serum NSE and reference values specific to
each technique have been established.29 It is important to
apply the appropriate reference range for the method
used. Our hospital employs the assay (i.e., an ECLIA kit)
that we used in this study with a normal range of
4.7e18 ng/mL that is based on adult testing but is applied
to all ages. The sample size for our study was limited;
however, the results suggest that serum NSE levels in pre-
term and term newborns differ from those in adults. To our
knowledge, the literature contains no reference values for
serum NSE in preterm and term newborns. We observed
ranges of 16.95e26.71 ng/mL in healthy preterm newborns
and 13.94e22.19 ng/mL in healthy term infants. Our find-
ings suggest that adult reference values should not be
applied to these age groups. Further investigation is war-
ranted with larger sample sizes and samples that include
subgroups categorized by gestational week.Conflicts of interest
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